Losartan vs Amlodipine: Side-Effect Profile Head-to-Head

How These Two Drugs Lower Blood Pressure Differently

Losartan blocks the angiotensin II type-1 receptor, reducing vasoconstriction and aldosterone secretion. Amlodipine inhibits L-type calcium channels in vascular smooth muscle, directly relaxing arterial walls. These distinct mechanisms produce overlapping efficacy but divergent side-effect profiles that matter when choosing a first-line agent.

Losartan belongs to the ARB class, which emerged in the 1990s as an alternative to ACE inhibitors for patients who could not tolerate cough or angioedema. The LIFE trial (N=9,193) established losartan's cardiovascular benefit in hypertensive patients with left ventricular hypertrophy, showing a 13% reduction in the composite endpoint of cardiovascular death, stroke, and myocardial infarction versus atenolol [1]. Amlodipine, a long-acting dihydropyridine, was validated in ASCOT-BPLA (N=19,257), where the amlodipine-based regimen reduced cardiovascular events and all-cause mortality compared with an atenolol-based strategy [2]. The ALLHAT trial (N=33,357) confirmed amlodipine's efficacy alongside chlorthalidone as a first-line option [3].

No large randomized trial has compared losartan directly to amlodipine as primary interventions. The VALUE trial (N=15,245) tested a related ARB, valsartan, against amlodipine and found similar cardiac outcomes but noted that amlodipine achieved faster blood pressure control in the first six months [4]. Side-effect data from these trials, combined with decades of post-marketing surveillance, provide the evidence base for the comparison below.

Peripheral Edema: Amlodipine's Signature Side Effect

Dose-dependent ankle swelling is the most frequent reason patients discontinue amlodipine. It occurs because arteriolar dilation increases capillary hydrostatic pressure without a corresponding venodilation, and it does not respond to diuretics.

The amlodipine FDA prescribing label reports peripheral edema rates of 1.8% at 2.5 mg, 3.0% at 5 mg, and 10.8% at 10 mg [5]. In ALLHAT, edema led to discontinuation in 2.1% of amlodipine-treated patients over 4.9 years of follow-up [3]. Women and older adults experience higher rates. A 2007 meta-analysis published in the American Journal of Hypertension (N=9,641) found that adding an ARB to amlodipine reduced edema incidence by approximately 40% compared to amlodipine uptitration alone [6]. This finding has shaped combination prescribing patterns. Many clinicians now pair amlodipine with losartan precisely to mitigate swelling.

Losartan, by contrast, does not cause peripheral edema at rates above placebo. The losartan prescribing information lists edema at <1% [7]. For patients whose primary concern is ankle swelling, this difference is decisive.

Hyperkalemia and Renal Considerations: The ARB Trade-Off

Losartan raises serum potassium by 0.1 to 0.3 mEq/L on average because it suppresses aldosterone-mediated potassium excretion. This effect is clinically relevant in patients with reduced kidney function, diabetes, or concurrent use of potassium-sparing agents.

In the LIFE trial, hyperkalemia (potassium >5.5 mEq/L) occurred in 1.5% of losartan-treated patients, compared with 0.4% in the atenolol group [1]. A 2014 systematic review in JAMA Internal Medicine found that ARBs as a class increased hyperkalemia risk with an odds ratio of 1.58 (95% CI 1.34 to 1.86) compared with non-RAAS-blocking antihypertensives [8]. The risk climbs sharply in patients with an eGFR <30 mL/min/1.73 m² or those already taking an ACE inhibitor or mineralocorticoid receptor antagonist.

Amlodipine does not affect the renin-angiotensin-aldosterone system and carries no hyperkalemia risk. It also does not require routine potassium monitoring, which reduces lab costs and patient burden. The 2017 ACC/AHA Hypertension Guideline notes that CCBs "do not require potassium or creatinine monitoring at the frequency recommended for RAAS inhibitors" [9]. For patients with stage 4 or 5 CKD who are not candidates for RAAS blockade, amlodipine offers a cleaner safety profile.

Losartan does carry a renoprotective advantage in diabetic nephropathy. The RENAAL trial (N=1,513) demonstrated a 16% reduction in doubling of serum creatinine and a 28% reduction in progression to end-stage renal disease compared with placebo [10]. This benefit comes with the trade-off of mandatory potassium and creatinine surveillance.

Dizziness, Headache, and Fatigue

Both drugs cause dizziness, but through different mechanisms. Losartan-related dizziness reflects a drop in systemic vascular resistance via RAAS suppression, while amlodipine-related dizziness is primarily vasodilatory. Frequency is similar at standard doses.

Losartan prescribing data report dizziness in 2.4% of patients (versus 1.3% on placebo) and fatigue in 2.0% [7]. Amlodipine's label reports dizziness at 1.1 to 3.4% depending on dose, headache at 7.3%, and fatigue at 4.5% [5]. Headache is more common with amlodipine than with losartan. This is consistent across dihydropyridine CCBs and reflects reflex sympathetic activation in response to peripheral vasodilation. The headache tends to be dose-related and often resolves within the first two weeks of therapy.

Fatigue reports differ modestly. In LIFE, losartan-treated patients reported less fatigue than atenolol-treated patients (a comparison that reflects beta-blocker sedation rather than ARB-specific fatigue). Neither losartan nor amlodipine causes the exercise intolerance or weight gain seen with older beta-blockers, a distinction that matters for physically active patients.

Cough: Why Neither Drug Is the Problem

ARBs were developed specifically to avoid the bradykinin-mediated cough that affects 5 to 20% of ACE inhibitor users. Losartan's cough rate in clinical trials was 0.7%, only marginally above placebo. Amlodipine's cough rate is approximately 0.1%.

The 2012 Cochrane review of ARBs versus ACE inhibitors confirmed that ARBs reduce cough-related discontinuation by 87% compared with ACE inhibitors (RR 0.13 to 95% CI 0.09 to 0.20) [11]. For patients switching from an ACE inhibitor because of persistent cough, both losartan and amlodipine are reasonable replacements. Neither carries meaningful cough liability. If a patient is already on losartan and develops cough, the drug is unlikely to be the cause. A pulmonary workup is warranted rather than a reflexive switch.

Metabolic and Sexual Side Effects

Neither losartan nor amlodipine worsens glucose metabolism, lipid profiles, or sexual function at standard doses. Both drugs are considered metabolically neutral by 2017 ACC/AHA guidelines, distinguishing them from thiazides at high doses and older beta-blockers [9].

Losartan has a unique property among ARBs: it is mildly uricosuric, lowering serum uric acid by 0.4 to 0.7 mg/dL through inhibition of URAT1 in the proximal tubule [12]. A post-hoc analysis of the LIFE trial found that losartan's uric acid reduction accounted for 29% of its stroke-prevention benefit [13]. No other ARB, and certainly not amlodipine, shares this characteristic. For hypertensive patients with coexisting gout or hyperuricemia, losartan offers a dual pharmacologic advantage that amlodipine cannot match.

Dr. Suzanne Oparil, former president of the American Heart Association, noted in a review for the Journal of the American Society of Hypertension: "Losartan's uricosuric effect is a clinically meaningful differentiator within the ARB class and may reduce cardiovascular risk beyond blood pressure lowering alone" [13].

Regarding sexual function, a 2015 meta-analysis in the Journal of Sexual Medicine (N=14,422) found no significant increase in erectile dysfunction with ARBs or CCBs compared with placebo [14]. Some data suggest ARBs may slightly improve sexual function scores relative to beta-blockers, but the effect size is small.

Serious Adverse Events: Angioedema, Hepatotoxicity, and Pregnancy Risk

Losartan carries a low but real risk of angioedema (estimated at 0.11 to 0.4%), particularly in patients with a history of ACE inhibitor-induced angioedema. Amlodipine does not cause angioedema. This distinction is clinically important for the estimated 0.1 to 0.7% of ACE inhibitor users who develop this potentially life-threatening reaction.

The 2008 ONTARGET/TRANSCEND analysis found that 2 to 6% of patients with prior ACE inhibitor angioedema experienced recurrence on an ARB [15]. Current ACC/AHA guidance permits cautious ARB use in these patients, but amlodipine avoids the question entirely.

Hepatotoxicity is rare with both drugs. Losartan undergoes hepatic metabolism via CYP2C9 and CYP3A4, and post-marketing reports include isolated cases of cholestatic and hepatocellular injury. The FDA label includes a precaution for hepatic impairment with a recommendation to consider a lower starting dose (25 mg) [7]. Amlodipine is also hepatically metabolized, and its label advises caution in severe hepatic impairment due to prolonged half-life. Neither drug requires routine liver function monitoring.

Pregnancy risk is the sharpest dividing line. Losartan, like all RAAS inhibitors, carries an FDA black-box warning for fetal toxicity. Exposure during the second and third trimesters causes oligohydramnios, renal failure, hypotension, and death in the fetus [7]. Women of reproductive age on losartan require documented contraception or a plan for drug discontinuation before conception. Amlodipine is FDA pregnancy category C (now removed under PLLR but historically assigned). Animal studies showed adverse fetal effects at high doses, but human data are limited. The 2017 ACC/AHA guideline recommends nifedipine or labetalol as preferred agents in pregnancy, not amlodipine, but amlodipine is not absolutely contraindicated the way losartan is [9].

Who Should Choose Which Drug

The best choice depends on the patient's comorbidities, lab values, and tolerance priorities. Dr. Paul Whelton, chair of the 2017 ACC/AHA Hypertension Guideline writing committee, stated: "Selection among first-line agents should be guided by compelling indications, contraindications, and patient preference rather than by a rigid class hierarchy" [9].

Choose losartan when the patient has diabetic nephropathy (RENAAL evidence [10]), left ventricular hypertrophy (LIFE evidence [1]), gout or hyperuricemia, or a history of ACE inhibitor-induced cough. Monitor potassium at baseline, two weeks after initiation, and at each dose change.

Choose amlodipine when the patient has stage 4 to 5 CKD without albuminuria, a history of angioedema on any RAAS inhibitor, or a strong preference to avoid blood draws. Warn about ankle swelling, particularly at the 10 mg dose, and consider adding a low-dose ARB if edema develops rather than discontinuing.

For patients who need both, the combination of an ARB with a CCB is guideline-endorsed as a preferred two-drug pairing. The 2018 ESC/ESH Hypertension Guidelines specifically recommend ARB plus CCB as a first-line single-pill combination for most hypertensive adults [16]. This approach captures the renoprotective and uricosuric benefits of losartan while offsetting amlodipine's edema with ARB-mediated venodilation. The starting combination of losartan 50 mg plus amlodipine 5 mg provides approximately 20/12 mmHg systolic/diastolic reduction in stage 2 hypertension, based on factorial dose-response data [16].